To move beyond the success of CAR T-cell therapy for B-cell malignancy, careful target
selection and new mechanisms of engineered T-cell control will be required. Promising …

Abstract The US Food and Drug Administration has approved 3 chimeric antigen receptor
(CAR) T-cell therapies. For continued breakthroughs, novel CAR designs are needed. This …

Following the landmark approvals by the United States Food and Drug Administration, the
adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells has now entered …

Neuroblastoma (NBL), the most frequent and lethal pediatric cancer of children in pre-school
age, is considered enigmatic in view of its extreme heterogeneity, from spontaneous …

Chimeric antigen receptor (CAR)-engineered T-cell therapy is a promising cancer treatment
strategy that harnesses the power of immunotherapy and exploits precision medicine. It …

Introduction: Neuroblastoma is a tumor of the developing sympathetic nervous system. Low
and intermediate-risk patients usually have good treatment outcomes, whereas high-risk …

Downregulation of HLA is one of the most common tumor escape mechanisms by enabling
tumors to persist in the presence of tumor-reactive T cells. HLA loss is particularly common …

The use of chimeric antigen receptor (CAR) modified T cells targeting human CD19 has
demonstrated great success in treating relapsed/refractory (r/r) Diffuse Large B Cell …

Chimeric antigen receptor (CAR) T cells therapy has proven to be extremely efficacious in
leukaemia and lymphoma patients. However, these exceptional results did not translate to …